TheracosBio is a biopharmaceutical company based in Sunnyvale, CA, dedicated to providing affordable medications for prevalent conditions. Their mission is to improve public health by ensuring access to new medications for patients with common diseases. Led by a team of experienced professionals, including President and CEO Brian Connelly, TheracosBio believes that appropriate pricing can meet their business needs while enabling improved access to the latest therapeutic technologies. They are currently focused on marketing Brenzavvy, a medication approved by the U.S. Food and Drug Administration in 2023.
With a strong leadership team, including Chief Financial Officer Jeffrey B. McGroarty and Intellectual Property and Communications expert Jeffrey B. Prince, TheracosBio is committed to advancing healthcare through innovation. Their team also includes experts in regulatory affairs, clinical operations, chemistry, manufacturing and controls, quality assurance, and supply chain management. By prioritizing affordability and accessibility, TheracosBio aims to make a positive impact on the lives of patients and contribute to the advancement of public health.
Generated from the website
